Back to Search
Start Over
Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure
- Source :
- EBioMedicine
- Publication Year :
- 2018
- Publisher :
- Elsevier, 2018.
-
Abstract
- Background Hepatic encephalopathy (HE), a severe neuropsychiatric complication, is associated with increased blood levels of ammonia and bile acids (BAs). We sought to determine (1) whether abnormally increased blood BAs in liver cirrhotic patients with HE is caused by elevation of apical sodium-dependent BA transporter (ASBT)-mediated BA reabsorption; and (2) whether increased BA reabsorption would exacerbate ammonia-induced brain injuries. Methods We quantitatively measured blood BA and ammonia levels in liver cirrhosis patients with or without HE and healthy controls. We characterized ASBT expression, BA profiles, and ammonia concentrations in a chronic liver disease (CLD) mouse model induced by streptozotocin-high fat diet (STZ-HFD) and an azoxymethane (AOM) - induced acute liver failure (ALF) mouse model. These two mouse models were treated with SC-435 (ASBT inhibitor) and budesonide (ASBT activator), respectively. Findings Blood concentrations of ammonia and conjugated BAs were substantially increased in cirrhotic patients with HE (n = 75) compared to cirrhotic patients without HE (n = 126). Pharmacological inhibition of the enterohepatic BA circulation using a luminal- restricted ASBT inhibitor, SC-435, in mice with AOM-induced ALF and STZ-HFD -induced CLD effectively reduced BA and ammonia concentrations in the blood and brain, and alleviated liver and brain damages. Budesonide treatment induced liver and brain damages in normal mice, and exacerbated these damages in AOM-treated mice. Interpretation ASBT mediated BA reabsorption increases intestinal luminal pH and facilitates conversion of intestinal ammonium to ammonia, leading to abnormally high levels of neurotoxic ammonia and cytotoxic BAs in the blood and brain. Inhibition of intestinal ASBT with SC-435 can effectively remove neurotoxic BAs and ammonia from the bloodstream and thus, mitigate liver and brain injuries resulting from liver failure.
- Subjects :
- 0301 basic medicine
Budesonide
Male
medicine.medical_specialty
Cirrhosis
Research paper
medicine.drug_class
Chronic liver disease
General Biochemistry, Genetics and Molecular Biology
Cell Line
Bile Acids and Salts
End Stage Liver Disease
03 medical and health sciences
chemistry.chemical_compound
Mice
Ammonia
Internal medicine
medicine
Animals
Humans
Hepatic encephalopathy
Bile acid
business.industry
Reabsorption
Azoxymethane
Transporter
General Medicine
Liver Failure, Acute
Middle Aged
medicine.disease
Bile acids
3. Good health
Disease Models, Animal
030104 developmental biology
Endocrinology
chemistry
Hepatic Encephalopathy
Apical sodium-dependent bile acid transporter
Female
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 23523964
- Volume :
- 37
- Database :
- OpenAIRE
- Journal :
- EBioMedicine
- Accession number :
- edsair.doi.dedup.....1f2071f4212b3001aef130c745f7efa4